Muhammadiyah Central Leadership to Build Infusion Fluid Factory, Targeting Operations in 2028
Jakarta (ANTARA) - The Central Leadership of Muhammadiyah is preparing the construction of an infusion fluid factory that will strengthen self-reliance in the health sector within the organisation through its new business entity, PT Suryavena Farma Indonesia.
“So far, Muhammadiyah has been strong in the health and education sectors. However, for the supply of medical equipment and medicines, it still relies on external parties,” said Director of PT Suryavena Farma Indonesia, Tatat Rahmita Utami, after the launch of PT Suryavena Farma Indonesia at the Muhammadiyah Dakwah Building, Jakarta, on Monday.
Tatat explained that Muhammadiyah currently has around 130 hospitals and more than 300 clinics spread across various regions in Indonesia. This number continues to increase every year, but it is not yet supported by its own upstream health industry.
According to Tatat, this situation has prompted Muhammadiyah to start producing medical needs independently, beginning with infusion fluids under the Suryavena brand.
Over the past two years, she said, Suryavena infusion fluid production has still been carried out through a toll manufacturing scheme or collaboration with other parties’ factories. This has caused several challenges, particularly regarding supply consistency.
“Because we are still piggybacking on other factories, there are supply limitations. Meanwhile, the internal needs of Muhammadiyah are quite substantial,” she stated.
To address this, Muhammadiyah has taken the initiative to build its own factory in the Karangploso area, Malang, East Java. This location was chosen because it is a national centre for the infusion fluid industry.
“The available land is around 14 hectares and has undergone feasibility tests, including water quality. The results meet the requirements for building an infusion fluid factory,” said Tatat.
She targets the factory construction to start soon, with operations beginning at the end of 2027 or early 2028. Funding will come from a combination of external financing, including banking and investors.
Currently, a feasibility study has been conducted involving ITB, as well as support from financial consultants for financing planning.
Tatat mentioned that the factory’s production capacity is targeted at 15 million bottles per year. Of this amount, around 13 million bottles will be allocated to meet Muhammadiyah’s internal needs, while the remainder has potential for general marketing.
Market demand for Suryavena products is quite high, she continued, because it offers competitive prices with good quality.
“Even outside Muhammadiyah hospitals, there is already a lot of interest, but currently it is still limited because production capacity is not yet optimal,” she said.